TG Therapeutics, Inc. Forecast, price target & analysts
TG Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
TG Therapeutics, Inc. Classifications & Recommendation:
TG Therapeutics, Inc. Price Target
| Target Price | $40.33 |
| Price | $28.53 |
| Potential |
41.37%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target TG Therapeutics, Inc. 2026 .
The average TG Therapeutics, Inc. target price is $40.33.
This is
41.37%
register free of charge
$55.00
92.78%
register free of charge
$10.00
64.95%
register free of charge
|
|
| A rating was issued by 8 analysts: 7 Analysts recommend TG Therapeutics, Inc. to buy, 0 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the TG Therapeutics, Inc. stock has an average upside potential 2026 of
41.37%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 233.66 | 321.49 |
| 8,274.91% | 37.59% | |
| EBITDA Margin | 9.01% | 20.99% |
| 100.13% | 132.88% | |
| Net Margin | 6.00% | 7.06% |
| 100.07% | 17.66% |
6 Analysts have issued a sales forecast TG Therapeutics, Inc. 2024 . The average TG Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an TG Therapeutics, Inc. EBITDA forecast 2024. The average TG Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 TG Therapeutics, Inc. Analysts have issued a net profit forecast 2024. The average TG Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 0.09 | 0.15 |
| 106.16% | 66.67% | |
| P/E | 195.79 | |
| EV/Sales | 13.54 |
7 Analysts have issued a TG Therapeutics, Inc. forecast for earnings per share. The average TG Therapeutics, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the TG Therapeutics, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
TG Therapeutics, Inc....
Current TG Therapeutics, Inc. Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Jan 15 2025 |
| JP Morgan | Locked ➜ Locked | Locked | Nov 25 2024 |
| Goldman Sachs | Locked ➜ Locked | Locked | Nov 05 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 05 2024 |
| TD Cowen | Locked ➜ Locked | Locked | Oct 29 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Sep 18 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Jan 15 2025 |
|
Locked
JP Morgan: Locked ➜ Locked
|
Nov 25 2024 |
|
Locked
Goldman Sachs: Locked ➜ Locked
|
Nov 05 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 05 2024 |
|
Locked
TD Cowen: Locked ➜ Locked
|
Oct 29 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Sep 18 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
